Literature DB >> 15008989

Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients.

C Hubeau1, R Le Naour, M Abély, J Hinnrasky, M Guenounou, D Gaillard, E Puchelle.   

Abstract

It is well documented that patients with cystic fibrosis (CF) are unable to clear persistent airway infections in spite of strong local inflammation, suggesting a dysregulation of immunity in CF. We and others have reported previously that T lymphocytes may play a prominent role in this immune imbalance. In the present work, we compared the reactivity of CD3+ T cells obtained from young CF patients in stable clinical conditions (n = 10, aged 9-16.5 years) to age-matched healthy subjects (n = 6, aged 9-13.5 years). Intracellular levels of interferon (IFN)-gamma, interleukin (IL)-2, IL-8 and IL-10 were determined by flow cytometry after whole blood culture. The data identified T lymphocyte subsets producing either low levels (M1) or high levels (M2) of cytokine under steady-state conditions. We found that the production of IFN-gamma and IL-10 by T lymphocytes was similar between young CF patients and healthy subjects. In contrast, after 4 h of activation with PMA and ionomycin, the percentage of T cells producing high levels of IL-2 (M2) was greater in CF patients (P = 0.02). Moreover, T cells from CF patients produced lower levels of IL-8, before and after activation (P = 0.007). We conclude that a systemic immune imbalance is present in young CF patients, even when clinically stable. This disorder is characterized by the capability of circulating T lymphocytes to produce low levels of IL-8 and by the emergence of more numerous T cells producing high levels of IL-2. This imbalance may contribute to immune dysregulation in CF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008989      PMCID: PMC1808972          DOI: 10.1111/j.1365-2249.2003.02385.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

Review 1.  Homeostasis of alpha beta TCR+ T cells.

Authors:  P Marrack; J Bender; D Hildeman; M Jordan; T Mitchell; M Murakami; A Sakamoto; B C Schaefer; B Swanson; J Kappler
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

Review 2.  Cellular and structural bases of chronic obstructive pulmonary disease.

Authors:  M Saetta; G Turato; P Maestrelli; C E Mapp; L M Fabbri
Journal:  Am J Respir Crit Care Med       Date:  2001-05       Impact factor: 21.405

3.  Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa.

Authors:  C Hubeau; M Lorenzato; J P Couetil; D Hubert; D Dusser; E Puchelle; D Gaillard
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

4.  The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type.

Authors:  C Moser; S Kjaergaard; T Pressler; A Kharazmi; C Koch; N Høiby
Journal:  APMIS       Date:  2000-05       Impact factor: 3.205

5.  High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content.

Authors:  O Tabary; S Escotte; J P Couetil; D Hubert; D Dusser; E Puchelle; J Jacquot
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

6.  Pseudomonas aeruginosa exoenzyme S induces transcriptional expression of proinflammatory cytokines and chemokines.

Authors:  S Epelman; T F Bruno; G G Neely; D E Woods; C H Mody
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

7.  Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes.

Authors:  R B Moss; Y P Hsu; L Olds
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

8.  Inflammation and infection in naive human cystic fibrosis airway grafts.

Authors:  R Tirouvanziam; S de Bentzmann; C Hubeau; J Hinnrasky; J Jacquot; B Péault; E Puchelle
Journal:  Am J Respir Cell Mol Biol       Date:  2000-08       Impact factor: 6.914

9.  Innate lung defenses and compromised Pseudomonas aeruginosa clearance in the malnourished mouse model of respiratory infections in cystic fibrosis.

Authors:  H Yu; S Z Nasr; V Deretic
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

Review 10.  Alveolar macrophage-T cell interactions during Th1-type sarcoid inflammation.

Authors:  C Agostini; M Facco; M Chilosi; G Semenzato
Journal:  Microsc Res Tech       Date:  2001-05-15       Impact factor: 2.769

View more
  12 in total

1.  Lymphocytes in cystic fibrosis lung disease: a tale of two immunities.

Authors:  R B Moss
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 2.  New insights into pulmonary inflammation in cystic fibrosis.

Authors:  S Rao; J Grigg
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

Review 3.  Azithromycin use in patients with cystic fibrosis.

Authors:  N Principi; F Blasi; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-17       Impact factor: 3.267

4.  Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells.

Authors:  K Sugiyama; R Shirai; H Mukae; H Ishimoto; T Nagata; N Sakamoto; H Ishii; S Nakayama; K Yanagihara; Y Mizuta; S Kohno
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

5.  Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis.

Authors:  Emanuela M Bruscia; Ping-Xia Zhang; Ayano Satoh; Christina Caputo; Ruslan Medzhitov; Ambika Shenoy; Marie E Egan; Diane S Krause
Journal:  J Immunol       Date:  2011-05-18       Impact factor: 5.422

6.  Platelet factor 4 is highly upregulated in dendritic cells after severe trauma.

Authors:  Marcus Maier; Emanuel V Geiger; Dirk Henrich; Carolyn Bendt; Sebastian Wutzler; Mark Lehnert; Ingo Marzi
Journal:  Mol Med       Date:  2009-08-27       Impact factor: 6.354

7.  A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients.

Authors:  V Lucidi; A E Tozzi; S Bella; A Turchetta
Journal:  BMC Pediatr       Date:  2006-05-24       Impact factor: 2.125

8.  Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.

Authors:  Veerle Reynders; Stefan Loitsch; Constanze Steinhauer; Thomas Wagner; Dieter Steinhilber; Joachim Bargon
Journal:  Respir Res       Date:  2006-07-30

9.  A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis.

Authors:  Silvia Moretti; Giorgia Renga; Vasilis Oikonomou; Claudia Galosi; Marilena Pariano; Rossana G Iannitti; Monica Borghi; Matteo Puccetti; Marco De Zuani; Carlo E Pucillo; Giuseppe Paolicelli; Teresa Zelante; Jean-Christophe Renauld; Oxana Bereshchenko; Paolo Sportoletti; Vincenzina Lucidi; Maria Chiara Russo; Carla Colombo; Ersilia Fiscarelli; Cornelia Lass-Flörl; Fabio Majo; Gabriella Ricciotti; Helmut Ellemunter; Luigi Ratclif; Vincenzo Nicola Talesa; Valerio Napolioni; Luigina Romani
Journal:  Nat Commun       Date:  2017-01-16       Impact factor: 14.919

10.  Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis.

Authors:  Theodore G Liou; Frederick R Adler; Ruth H Keogh; Yanping Li; Judy L Jensen; William Walsh; Kristyn Packer; Teresa Clark; Holly Carveth; Jun Chen; Shaunessy L Rogers; Christen Lane; James Moore; Anne Sturrock; Robert Paine; David R Cox; John R Hoidal
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.